Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home Item
Seminar: Integrated Bioelectronic Systems for Biomedical Research and Healthcare: Materials, Electronics, and Computing , homeFeb. 7, 2023, 12 p.m. | Wei Ouyang, Ph.D., Postdoctoral Fellow, Querrey Simpson Institute for Bioelectronics, Northwestern University | Seminar
-
Home Item
Seminar: Molecular Targets of Prenatal Alcohol Exposure During Early Brain Development , homeFeb. 8, 2023, 2 p.m. | Karen Boschen, Ph.D., Postdoctoral Research Associate, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine | Seminar
-
Home Item
In Person Lecture: Developmental Cognitive Neuroscience in the Era of Big Data , homeFeb. 9, 2023, 5:30 p.m. (Reception at 5 p.m.) | Damien Fair, PA-C, Ph.D., Professor, Institute of Child Development, Department of Pediatrics, College of Education and Human Development, University of Minnesota Medical School | Maury Strauss Distinguished Public Lecture
-
Home Item
In Person Seminar: Pathogenic Mechanisms and Novel Therapies for Immune Neoplasms , homeFeb. 10, 2023, 11 a.m. | Ari Melnick, M.D., Gebroe Family Professor of Hematology/Oncology, and Director, Sackler Center for Biomedical and Physical Sciences, Weill Medical College, Cornell University | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Group
-
Home Item
In Person Seminar: Behavioral Economic Approaches for Measuring Substance Use Severity and Motivating Change , homeFeb. 17, 2023, 11:00 am. | James G. Murphy, Ph.D., Professor, Department of Psychology, University of Memphis | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Addiction Recovery Research Center and Center for Health Behaviors Research
-
Home Item
In Person Seminar: Functional MRI of Dynamic Physiological States , homeFeb. 24 2023, 11:00 a.m. | Catherine Chang, Ph.D., Assistant Professor, Department of Electrical Engineering and Computer Science, Vanderbilt University | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research